Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 766 of 5804
-
Off-the-Shelf CAR t cells take on Hard-to-Treat myeloma
Disease control CompletedThe purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and/…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for rare ovarian cancer: could hormone therapy replace chemo?
Disease control OngoingThis phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made …
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug shows promise in slowing advanced breast cancer with ESR1 mutation
Disease control CompletedThis is an open label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have disease …
Phase: PHASE2 • Sponsor: Sermonix Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise for resistant lung cancer in early trial
Disease control OngoingThis study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-s…
Phase: PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could your own immune cells fight liver cancer? new trial aims to find out
Disease control Recruiting nowThis early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in combination with immune checkpoint inhibition (with bevacizumab and atezolizumab or druvalumab) in treating patients liver cancer that cannot be removed by surgery (unr…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Chagas drug shows promise for kids in landmark trial
Disease control OngoingThis study evaluate the efficacy and safety of benznidazole in the treatment of chronic indeterminate Chagas disease in children. All subjects will receive benznidazole and results will be compared to historically to a placebo arm.
Phase: PHASE3 • Sponsor: Insud Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Shorter chemo before transplant may cut severe side effects for blood cancer patients
Disease control OngoingThe purpose of this study is to see if a condensed version of the chemotherapy regimen busulfan, melphalan, fludarabine (bu/mel/flu) and the drug antithymocyte globulin (ATG-also referred to as rATG or thymoglobulin) can have the same or fewer number of severe side effects in peo…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThe purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients wi…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Engineered immune cells take aim at rare blood cancer
Disease control Recruiting nowThis is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study participants and the immune T cells will be separated. T cells will be genetically modified in …
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New daily pill shows promise in controlling leukemia
Disease control CompletedThis is a global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts:…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New heart valve offers hope for High-Risk patients
Disease control OngoingThe purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30…
Phase: NA • Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Hearts with hepatitis c: a new hope for transplant patients?
Disease control Recruiting nowIn this study we seek to test the hypothesis that safety and clinical outcomes after cardiac transplantation utilizing HCV NAT+ donor organs as currently performed are acceptable.
Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug cocktail aims to halt smoldering myeloma before it strikes
Disease control Recruiting nowThis phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor ce…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a drug combo stop AML from coming back?
Disease control OngoingThis phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission. Drugs used in chemotherapy, such as azacitidine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for tough leukemia: experimental drug targets genetic flaw
Disease control OngoingIn this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Phase 1b, and Phase 2 portions), ziftomenib will be evaluated in patients with rela…
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New immunotherapy combo shows promise for tough lung cancer
Disease control CompletedThis is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10+ Chemotherapy vs placebo+Chemotherapy in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer. Eligible subjects in this study will…
Phase: PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Killer virus turned against childhood brain cancer
Disease control Recruiting nowThis study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell ki…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Engineered immune cells take aim at tough blood cancers
Disease control CompletedThe primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
Phase: PHASE1 • Sponsor: Matthew Frank • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug cocktail aims to control rare blood cancer without chemo
Disease control OngoingIn Waldenström macroglobulinemia (WM) conventional chemotherapy induces only low complete remission (CR) rates and responses of short duration compared to other indolent lymphomas. Thus innovative approaches are needed which combine excellent activity and tolerability in patients…
Phase: PHASE2 • Sponsor: Christian Buske • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New drug combo shows promise for chinese men with advanced prostate cancer
Disease control OngoingThe purpose of this study was to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC). The study was conducted in two phases: Double-Blind tre…
Phase: PHASE3 • Sponsor: Astellas (Beijing) Pharmaceutical R&D Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC